INDICATION

Aptensio XR® (methylphenidate HCl extended-release) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

For US Healthcare Professionals

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Aptensio XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

Image portrays a 12‐hour day when Aptensio XR is taken at 7:00 AM.
.
Image portrays a 12‐hour day when Aptensio XR is taken at 7:00 AM.

Ready to go, from hour 1 to hour 12

Once-daily Aptensio XR starts working by hour 1 and controls ADHD symptoms until hour 121

Aptensio XR® (methylphenidate HCl extended-release) demonstrated statistical significance at all time points tested post dose: 1, 2, 3, 4.5, 6, 7.5, 9, 10.5, and 12 hours.1

.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Aptensio XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.